Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease

Sumida, Yoshio; Yoneda, Masashi; Seko, Yuya; Ishiba, Hiroshi; Hara, Tasuku; Toyoda, Hidenori; Yasuda, Satoshi; Kumada, Takashi; Hayashi, Hideki; Kobayashi, Takashi; Imajo, Kento; Yoneda, Masato; Tada, Toshifumi; Kawaguchi, Takumi; Eguchi, Yuichiro; Oeda, Satoshi; Takahashi, Hirokazu; Tomita, Eiichi; Okanoue, Takeshi; Nakajima, Atsushi

doi:10.3390/diagnostics10080579

Cited by 27 publications

(27 citation statements)

References 96 publications

(130 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it has been suggested that NAFLD patients with cirrhosis or possible fibrosis or diabetes mellitus should have 6 monthly surveillances via ultrasound (US) and tumor markers (AFP, AFP-L3 and DCP). Abdominal fat can be a hindrance, hence, patients with obesity can be alternatively surveilled using CT-Scan or magnetic resonance imaging[ 77 ].…”

Section: Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

Hanif¹,

Ali²,

Susheela³

et al. 2022

WJG

126

View full text Add to dashboard Cite

Alpha-fetoprotein (AFP) is an oncofetal glycoprotein that has been used as a tumor marker for hepatocellular carcinoma (HCC) in combination with ultrasound and other imaging modalities. Its utility is limited because of both low sensitivity and specificity, and discrepancies among the different methods of measurements. Moreover, its accuracy varies according to patient characteristics and the AFP cut-off values used. Combination of AFP with novel biomarkers such as AFP-L3, Golgi specific membrane protein (GP73) and des-gamma-carboxyprothrombin significantly improved its accuracy in detecting HCC. Increased AFP level could also signify severity of hepatic destruction and subsequent regeneration and is commonly observed in patients with acute and chronic liver conditions and cirrhosis. Hereditary and other non-hepatic disorders can also cause AFP elevation.

show abstract

Section: Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

Hanif¹,

Ali²,

Susheela³

et al. 2022

WJG

126

View full text Add to dashboard Cite

show abstract

“…Because the main causes of death are cardiovascular disease, cancers and liver‐related disease, ( 2 ) early detection and estimation of liver fibrosis are important. ( 3,4 )…”

mentioning

confidence: 99%

Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes

Ishiba¹,

Sumida

Seko³

et al. 2020

Hepatol Commun

Self Cite

View full text Add to dashboard Cite

This study aimed to examine whether the diagnostic accuracy of four noninvasive tests (NITs) for detecting advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is maintained or is inferior to with or without the presence of type 2 diabetes. Overall, 874 patients with biopsy‐proven NAFLD were enrolled. After propensity‐score matching by age, sex, and the prevalence of dyslipidemia, 311 patients were enrolled in each group of with or without diabetes. To evaluate the effect of diabetes, we compared the diagnostic accuracy of the fibrosis‐4 (FIB‐4) index, the NAFLD fibrosis score (NFS), the aspartate aminotransferase to platelet ratio index (APRI), and type IV collagen 7S (COL4‐7S) in patients with NAFLD with and without diabetes. The areas under the receiver operating characteristic curve (AUROC) for identifying advanced fibrosis in patients without diabetes were 0.879 for the FIB‐4 index, 0.851 for the NFS, 0.862 for the APRI, and 0.883 for COL4‐7S. The AUROCs in patients with diabetes were 0.790 for the FIB‐4 index, 0.784 for the NFS, 0.771 for the APRI, and 0.872 for COL4‐7S. The AUROC of COL4‐7S was significantly larger than that of the other NITs in patients with NAFLD with diabetes than in those without diabetes. The optimal high and low cutoff points of COL4‐7S were 5.9 ng/mL and 4.8 ng/mL, respectively. At the low cutoff point, the accuracy of COL4‐7S was better than that of the other NITs, especially in patients with diabetes. Conclusion: COL4‐7S measurement might be the best NIT for identifying advanced fibrosis in NAFLD, especially in NAFLD with diabetes.

show abstract

“…Finally, the combination of different biomarkers with clinical and/or demographic characteristics into simple prediction models allowed the further improvement of the diagnostic accuracy for HCC detection [ 52 ]. However, the majority of these models have been developed and validated in cohorts of patients chronically infected with HBV or HCV [ 28 , 53 , 54 , 55 ]; to the best of our knowledge, only the GALAD score was tested in the setting of NAFLD, showing a high performance for the identification of patients with HCC [ 56 ].…”

Section: Discussionmentioning

confidence: 99%

Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease

Caviglia

Armandi

Rosso

et al. 2021

Cancers

View full text Add to dashboard Cite

Current surveillance strategy for patients with nonalcoholic fatty liver disease (NAFLD) at risk of hepatocellular carcinoma (HCC) development is unsatisfactory. We aimed to investigate the diagnostic accuracy of alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II), glypican-3 (GPC-3), adiponectin, leptin and interleukin-6 (IL-6), alone or in combination, for the discrimination between NAFLD patients with or without HCC. The biomarkers were investigated in a cohort of 191 NAFLD patients (median age 62, 54–68 years; 121 males and 70 females) with advanced fibrosis/cirrhosis, 72 of whom had a diagnosis of HCC. PIVKA-II showed the best performance for the detection of HCC with an area under the curve (AUC) of 0.853, followed by adiponectin (AUC = 0.770), AFP (AUC = 0.763), GPC-3 (AUC = 0.759) and by IL-6 (AUC = 0.731), while the leptin values were not different between patients with and without HCC. The accuracy of the biomarkers’ combination was assessed by a stratified cross-validation approach. The combination of age, gender, PIVKA-II, GPC-3 and adiponectin further improved the diagnostic accuracy (AUC = 0.948); the model correctly identified the 87% of the patients. In conclusion, we developed a model with excellent accuracy for the detection of HCC that may be useful to improve the surveillance of NAFLD patients at risk of tumor development.

show abstract

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease

Cited by 27 publications

References 96 publications

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes

Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease

Contact Info

Product

Resources

About